{"filing":{"accession_number":"0001628280-26-053328","cik":"0001831097","ticker":"AGL","company_name":"agilon health, inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"agl-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1831097/000162828026053328/agl-20260805.htm"},"events":[{"id":24961,"run_id":22631,"accession_number":"0001628280-26-053328","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing agilon health's financial results for Q2 2026 and six months ended June 30, 2026. The press release (Exhibit 99.1) reports total revenues of $1.49 billion (7% increase YoY), gross profit of $107 million (vs. prior-year loss of $52 million), net income of $18 million (vs. prior-year loss of $104 million), and medical margin of $197 million (vs. negative $53 million). The company also raised full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA. This is a material disclosure affecting investor assessment of the registrant's financial performance and outlook.","company_name":"agilon health, inc.","ticker":"AGL","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25672,"accession_number":"0001628280-26-053328","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing agilon health's financial results for Q2 2026 and six months ended June 30, 2026. The press release (Exhibit 99.1) reports total revenues of $1.49 billion (7% increase YoY), gross profit of $107 million (vs. prior-year loss of $52 million), net income of $18 million (vs. prior-year loss of $104 million), and medical margin of $197 million (vs. negative $53 million). The company also raised full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA. This is a material disclosure affecting investor assessment of the registrant's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T03:21:51.985598+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25672,"accession_number":"0001628280-26-053328","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing agilon health's financial results for Q2 2026 and six months ended June 30, 2026. The press release (Exhibit 99.1) reports total revenues of $1.49 billion (7% increase YoY), gross profit of $107 million (vs. prior-year loss of $52 million), net income of $18 million (vs. prior-year loss of $104 million), and medical margin of $197 million (vs. negative $53 million). The company also raised full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA. This is a material disclosure affecting investor assessment of the registrant's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T03:21:51.985598+00:00","company_name":"agilon health, inc.","ticker":"AGL","filing_date":"2026-08-05"}]}